OB3 Stock Overview
A life sciences company, engages in the discovery and development of microbiome modulators in the United Kingdom, the United States, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OptiBiotix Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.15 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.12 |
| Beta | 1.74 |
| 11 Month Change | 0% |
| 3 Month Change | -41.41% |
| 1 Year Change | -49.32% |
| 33 Year Change | -67.53% |
| 5 Year Change | -73.21% |
| Change since IPO | -82.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| OB3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.3% | 0.8% | 0.8% |
| 1Y | -49.3% | -18.3% | 8.6% |
Return vs Industry: OB3 underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: OB3 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| OB3 volatility | |
|---|---|
| OB3 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OB3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OB3's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 10 | Stephen O'Hara | optibiotix.com |
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators in the United Kingdom, the United States, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; CholBiome, a food supplement for reducing cholesterol and blood pressure; LPGOS, a galactooligosaccharide that is used in food products and applications, which helps reduce cardiovascular risk factors and enhance health; and Sweetbiotix, a low calorie sweetener for food and beverages.
OptiBiotix Health Plc Fundamentals Summary
| OB3 fundamental statistics | |
|---|---|
| Market cap | €15.56m |
| Earnings (TTM) | -€3.58m |
| Revenue (TTM) | €682.03k |
22.8x
P/S Ratio-4.3x
P/E RatioIs OB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OB3 income statement (TTM) | |
|---|---|
| Revenue | UK£569.00k |
| Cost of Revenue | UK£296.00k |
| Gross Profit | UK£273.00k |
| Other Expenses | UK£3.26m |
| Earnings | -UK£2.98m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 47.98% |
| Net Profit Margin | -524.43% |
| Debt/Equity Ratio | 0% |
How did OB3 perform over the long term?
See historical performance and comparison